)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Stryker
Stryker (SYK) investor relations material
Stryker Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
Q3 net sales rose 7.7% to $6,520M, with organic growth driven primarily by higher unit volume; adjusted diluted EPS increased 10.3% to $3.52.
Results fell short of expectations despite solid underlying fundamentals; reported net earnings declined 12.3% to $753M, including a $293M Peripheral Vascular goodwill and other impairment.
Spencer Stiles was appointed next CEO after Kevin Lobo’s final earnings call as CEO.
Financial highlights
Adjusted gross margin was 65.4%, up 40 bps; adjusted operating margin was 26.2%, up 60 bps.
Reported gross margin rose to 65.2% from 63.6%; reported operating margin was 15.9% versus 18.7%.
Adjusted net earnings increased 10.1% to $1.4B; adjusted diluted EPS rose 10.3% to $3.52.
Nine-month net earnings rose 15.7% to $2.77B and diluted EPS increased 15.5% to $7.19; adjusted diluted EPS rose 7.1% to $9.81.
Adjusted other income and expense was $91M, down $25M YoY; Q3 adjusted tax rate was 16%.
Outlook and guidance
FY26 organic net sales growth guidance is 6.5%–7.0%; adjusted diluted EPS guidance is $14.80–$14.90.
Q4 organic growth is expected to be similar to Q3, assuming a continued Q3 procedure environment and strong capital demand.
FY adjusted other income and expense is expected to be ~$400M; full-year effective tax rate outlook is 15.5%–16%.
Formal 2027 guidance is expected early next year; current expectations are growth at the high end of markets and continued year-over-year margin improvement.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Stryker
- Supply challenges persist in key segments, but strong capital demand and new products support growth.SYK
Wells Fargo 21st Annual Healthcare Conference - Q2 sales rose 9.4% and adjusted EPS climbed 17.9%, driven by strong recovery and volume growth.SYKQ2 2026
- Full-year outlook remains strong, with robust recovery and innovation driving growth.SYKBank of America Global Healthcare Conference 2026
- Strong sales growth, innovation, and all proposals approved; outlook remains robust.SYKAGM 2026
- Cyber incident pressured Q1 margins, but sales rose 2.6% and full-year guidance is reaffirmed.SYKQ1 2026
- Q3 net sales up 11.9% and adjusted EPS up 16.7%, with strong 2024 outlook.SYKQ3 2024
- Growth driven by innovation, robotics, and portfolio shifts, with margin and global expansion in focus.SYKCiti’s 2025 Medtech and Life Sciences Access Day
- Raised 2025 outlook after double-digit organic growth and Inari acquisition, despite margin pressure.SYKQ1 2025
- Double-digit organic growth, margin expansion, and strategic moves set up a strong 2025 outlook.SYKQ4 2024
Next Stryker earnings date
Jefferies Global Healthcare Conference17 Nov, 2026
Stryker
Next Stryker earnings date
Jefferies Global Healthcare Conference17 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
A Pioneer in Medical Technologies
Stryker Corporation is an American medical technology company listed on the NYSE. Headquartered in Kalamazoo, Michigan, the company's operations extend across the globe, serving customers in over 100 countries. Stryker was founded in 1941 by Dr. Homer Stryker, an orthopedic surgeon from Michigan, the company has anchored its reputation on its range of medical devices. Stryker's products encompass a vast segment with everything from orthopedic implants to surgical instruments, and even hospital beds.
Building Upon Dr. Stryker’s Legacy
Dr. Homer Stryker's initial inventions, such as the mobile hospital bed and the turning frame, set the stage for the company's trajectory. Over the years, Stryker Corporation expanded its portfolio, venturing into various medical specialties, such as neurotechnology, spinal surgery, and endoscopy. Strategic acquisitions have played a crucial role in Stryker's growth and the company has absorbed various businesses within the industry, diversifying and expanding its portfolio. When looking at publicly traded peers to Stryker we find names like Medtronic and Abbott Laboratories as well as numerous divisions of massive international corporations such as GE.
Three Focus Areas
Stryker's products can be broadly categorized into three major sectors: Orthopedics, MedSurg, and Neurotechnology & Spine.
The Orthopedics division focuses on joint replacements, trauma and extremities, and other orthopedic surgeries. Products like hip and knee joint replacements and bone cement fall under this bracket.
MedSurg encompasses a wider spectrum. This category includes surgical equipment, navigation systems, patient-handling solutions, and emergency medical equipment. Noteworthy mentions include the power tools for precise bone surgeries and the 1588 AIM camera system for endoscopic surgeries.
The Neurotechnology & Spine department designs and manufactures equipment for the intricacies of neuro and spine surgeries. This division offers products like the Neuroform Atlas Stent System for brain aneurysm treatment and the LITe Decompression System for spine surgeries.
Dedicated Research and Development
Behind Stryker's extensive product portfolio lies its steadfast commitment to research and development. The company continually invests in R&D, ensuring its products not only meet but often exceed industry standards. This commitment to innovation is evident in the company's historically consistent rollout of advanced medical devices, many of which have been firsts in their respective fields.